Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases

World Journal of Gastroenterology

Volumn 22, Issue 11, 2016, Pages 3127-3149

  Alper Sag, Alan ^a   Selcukbiricik, Fatih ^a   Mandel, Nil Molinas ^a  

^a KOÇ UNIVERSITY   (Turkey)

Author keywords

And leucovorin protocol; Antineoplastic agents; Chemoembolization; Colonic neoplasms; FOLFOX protocol; Immunotherapy; Irinotecan, 5 flurouracil; Microwave ablation; Neoplasm metastasis; Radiofrequency ablation; Rectal neoplasms; Therapeutic

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DABRAFENIB; FLUORODEOXYGLUCOSE; FLUOROURACIL; FOLINIC ACID; GENISTEIN; IRINOTECAN; MITOMYCIN; NIVOLUMAB; OXALIPLATIN; PANITUMUMAB; PEMBROLIZUMAB; REGORAFENIB; RUXOLITINIB; TRAMETINIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VELIPARIB; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOEMBOLIZATION; CRYOABLATION; DIFFUSION WEIGHTED IMAGING; DISTANT METASTASIS; ELECTROPORATION; EVIDENCE BASED PRACTICE; FATTY LIVER; FOLLOW UP; HUMAN; IMMUNOMODULATION; INTERVENTIONAL RADIOLOGY; LIVER FIBROSIS; LOCAL THERAPY; LUNG METASTASIS; METASTATIC COLORECTAL CANCER; MINIMALLY INVASIVE PROCEDURE; PARENTERAL DRUG ADMINISTRATION; PATIENT SELECTION; PROGRESSION FREE SURVIVAL; REVIEW; RISK FACTOR; SYSTEMIC DISEASE; SYSTEMIC THERAPY; ABLATION THERAPY; CANCER STAGING; COLORECTAL NEOPLASMS; EVIDENCE BASED MEDICINE; IMMUNOTHERAPY; LIVER NEOPLASMS; MORTALITY; ONCOLOGY; PATHOLOGY; SECONDARY; TREATMENT OUTCOME;

ABLATION TECHNIQUES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOEMBOLIZATION, THERAPEUTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MEDICAL ONCOLOGY; NEOPLASM STAGING; RADIOGRAPHY, INTERVENTIONAL; RADIOLOGY, INTERVENTIONAL; TREATMENT OUTCOME;

EID: 84960863524     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i11.3127     Document Type: Review

References (137)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29. [PMID: 25559415. DOI: 10.3322/caac.21254
2. Li FY, Lai MD. Colorectal cancer, one entity or three. J Zhejiang Univ Sci B 2009; 10: 219-229. [PMID: 19283877. DOI: 10.1631/jzus.B0820273
3. Centers for Disease Control and Prevention, National Center for Health Statistics. National Health Interview Surveys, 2000, 2013. Public use data files: 2001, 2014
4. Gillams A, Goldberg N, Ahmed M, Bale R, Breen D, Callstrom M, Chen MH, Choi BI, de Baere T, Dupuy D, Gangi A, Gervais D, Helmberger T, Jung EM, Lee F, Lencioni R, Liang P, Livraghi T, Lu D, Meloni F, Pereira P, Piscaglia F, Rhim H, Salem R, Sofocleous C, Solomon SB, Soulen M, Tanaka M, Vogl T, Wood B, Solbiati L. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontières meeting 2013. Eur Radiol 2015; 25: 3438-3454. [PMID: 25994193. DOI: 10.1007/s00330-015-3779-z
5. Almersjö O, Bengmark S, Hafström L. Liver metastases found by follow-up of patients operated on for colorectal cancer. Cancer 1976; 37: 1454-1457. [PMID: 4218
6. Bengmark S, Hafström L. The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 1969; 23: 198-202. [PMID: 5763253
7. Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 2007; 11: 1057-1077. [PMID: 17530336. DOI: 10.1007/s11605-006-0061-3
8. Kemeny N, Fata F. Arterial, portal, or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma. J Hepatobiliary Pancreat Surg 1999; 6: 39-49. [PMID: 10436236
9. Seifert JK, Junginger T, Morris DL. A collective review of the world literature on hepatic cryotherapy. J R Coll Surg Edinb 1998; 43: 141-154. [PMID: 9654872
10. Brouquet A, Mortenson MM, Vauthey JN, Rodriguez-Bigas MA, Overman MJ, Chang GJ, Kopetz S, Garrett C, Curley SA, Abdalla EK. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg 2010; 210: 934-941. [PMID: 20510802. DOI: 10.1016/j.jamcollsurg.2010.02.039
11. Bolton JS, Fuhrman GM. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg 2000; 231: 743-751. [PMID: 10767796
12. Reddy SK, Pawlik TM, Zorzi D, Gleisner AL, Ribero D, Assumpcao L, Barbas AS, Abdalla EK, Choti MA, Vauthey JN, Ludwig KA, Mantyh CR, Morse MA, Clary BM. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol 2007; 14: 3481-3491. [PMID: 17805933. DOI: 10.1245/s10434-007-9522-5
13. Tanaka K, Shimada H, Matsuo K, Nagano Y, Endo I, Sekido H, Togo S. Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. Surgery 2004; 136: 650-659. [PMID: 15349115. DOI: 10.1016/j.surg.2004.02.012
14. Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, Mitry E, Rougier P, Nordlinger B. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24: 3939-3945. [PMID: 16921046. DOI: 10.1200/jco.2006.05.8727
15. Auer RC, White RR, Kemeny NE, Schwartz LH, Shia J, Blumgart LH, Dematteo RP, Fong Y, Jarnagin WR, D'Angelica MI. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010; 116: 1502-1509. [PMID: 20120032. DOI: 10.1002/cncr.24912
16. Elias D, Goere D, Boige V, Kohneh-Sharhi N, Malka D, Tomasic G, Dromain C, Ducreux M. Outcome of posthepatectomymissing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-Arterial hepatic oxaliplatin. Ann Surg Oncol 2007; 14: 3188-3194. [PMID: 17705091. DOI: 10.1245/s10434-007-9482-9
17. Elias D, Youssef O, Sideris L, Dromain C, Baton O, Boige V, Ducreux M. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 2004; 86: 4-9. [PMID: 15048673. DOI: 10.1002/jso.20039
18. Tanaka K, Takakura H, Takeda K, Matsuo K, Nagano Y, Endo I. Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases. Ann Surg 2009; 250: 935-942. [PMID: 19953712
19. van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg 2010; 14: 1691-1700. [PMID: 20839072. DOI: 10.1007/s11605-010-1348-y
20. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016. [PMID: 18358928. DOI: 10.1016/S0140-6736(08)60455-9
21. Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Köhne CH. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol 2014; 25: 1018-1025. [PMID: 24585720. DOI: 10.1093/annonc/mdu088
22. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671. [PMID: 19114683. DOI: 10.1200/JCO.2008.20.8397
23. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417. [PMID: 19339720. DOI: 10.1056/NEJMoa0805019
24. Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, Ye QH, Yu Y, Xu B, Qin XY, Xu J. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-Type unresectable colorectal liver-limited metastases. J Clin Oncol 2013; 31: 1931-1938. [PMID: 23569301. DOI: 10.1200/JCO.2012.44.8308
25. Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W, Spadafora S, Amado RG, Hogan N, Peeters M. An open-label, single-Arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008; 19: 92-98. [PMID: 17785764. DOI: 10.1093/annonc/mdm399
26. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-Type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634. [PMID: 18316791. DOI: 10.1200/jco.2007.14.7116
27. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG. Superiority of oxaliplatin and fluorouracilleucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracilleucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-2069. [PMID: 12775730. DOI: 10.1200/jco.2003.11.126
28. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947. [PMID: 10944126
29. Grothey A, Deschler, B., Kroening, H. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly highdose 24h 5-FU infusion/FA oxaliplatin in advanced colorectal cancer. Proc Am Soc Clin Oncol 2002; 21: 129a (abstr 512
30. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Lévi F. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. Linchuang Zhongliu Zazhi 2000; 18: 136-147
31. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047. [PMID: 10744089
32. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-2292. [PMID: 11304782
33. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097-4106. [PMID: 11689577
34. Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 2010; 11: 853-860. [PMID: 20708966. DOI: 10.1016/s1470-2045(10)70181-9
35. Guo Y, Shi M, Shen X, Yang C, Yang L, Zhang J. Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-Analysis. Clin Colorectal Cancer 2014; 13: 110-118. [PMID: 24461997. DOI: 10.1016/j.clcc.2013.12.004
36. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30: 3499-3506. [PMID: 22949147. DOI: 10.1200/jco.2012.42.8201
37. Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37. [PMID: 23168366. DOI: 10.1016/s1470-2045(12)70477-1
38. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-312. [PMID: 23177514. DOI: 10.1016/s0140-6736(12)61900-x
39. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-3683. [PMID: 19470929. DOI: 10.1200/jco.2008.20.5278
40. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311-2319. [PMID: 18390971. DOI: 10.1200/jco.2007.13.1193
41. Damjanov N, Weiss J, Haller DG. Resection of the primary colorectal cancer is not necessary in nonobstructed patients with metastatic disease. Oncologist 2009; 14: 963-969. [PMID: 19819916. DOI: 10.1634/theoncologist.2009-0022
42. Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, Weiser M, Temple LK, Wong WD, Paty PB. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009; 27: 3379-3384. [PMID: 19487380. DOI: 10.1200/jco.2008.20.9817
43. Liccioni A, Reig M, Bruix J. Treatment of hepatocellular carcinoma. Dig Dis 2014; 32: 554-563. [PMID: 25034288. DOI: 10.1159/000360501
44. Livraghi T, Solbiati L, Meloni F, Ierace T, Goldberg SN, Gazelle GS. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the test-of-Time approach. Cancer 2003; 97: 3027-3035. [PMID: 12784338. DOI: 10.1002/cncr.11426
45. Fujisawa S, Romin Y, Barlas A, Petrovic LM, Turkekul M, Fan N, Xu K, Garcia AR, Monette S, Klimstra DS, Erinjeri JP, Solomon SB, Manova-Todorova K, Sofocleous CT. Evaluation of YOPRO-1 as an early marker of apoptosis following radiofrequency ablation of colon cancer liver metastases. Cytotechnology 2014; 66: 259-273. [PMID: 24065619. DOI: 10.1007/s10616-013-9565-3
46. Makino Y, Imai Y, Igura T, Hori M, Fukuda K, Sawai Y, Kogita S, Fujita N, Takehara T, Murakami T. Comparative evaluation of three-dimensional Gd-EOB-DTPA-enhanced MR fusion imaging with CT fusion imaging in the assessment of treatment effect of radiofrequency ablation of hepatocellular carcinoma. Abdom Imaging 2015; 40: 102-111. [PMID: 25052767. DOI: 10.1007/s00261-014-0201-2
47. Rempp H, Clasen S, Pereira PL. Image-based monitoring of magnetic resonance-guided thermoablative therapies for liver tumors. Cardiovasc Intervent Radiol 2012; 35: 1281-1294. [PMID: 21785888. DOI: 10.1007/s00270-011-0227-6
48. Mauri G, Porazzi E, Cova L, Restelli U, Tondolo T, Bonfanti M, Cerri A, Ierace T, Croce D, Solbiati L. Intraprocedural contrastenhanced ultrasound (CEUS) in liver percutaneous radiofrequency ablation: clinical impact and health technology assessment. Insights Imaging 2014; 5: 209-216. [PMID: 24563244. DOI: 10.1007/s13244-014-0315-7
49. Olaf Dössel WCS. IFMBE Proceedings, World Congress on Medical Physics and Biomedical Engineering 7-12 September, 2009 Munich Germany. Surgery, Minimal Invasive Interventions, Endoscopy, and IMage Guided Therapy, 2009: Volume 25/6
50. Shyn PB, Tatli S, Sahni VA, Sadow CA, Forgione K, Mauri G, Morrison PR, Catalano PJ, Silverman SG. PET/CT-guided percutaneous liver mass biopsies and ablations: targeting accuracy of a single 20 s breath-hold PET acquisition. Clin Radiol 2014; 69: 410-415. [PMID: 24411824. DOI: 10.1016/j.crad.2013.11.013
51. Mauri G, Cova L, De Beni S, Ierace T, Tondolo T, Cerri A, Goldberg SN, Solbiati L. Real-Time US-CT/MRI image fusion for guidance of thermal ablation of liver tumors undetectable with US: results in 295 cases. Cardiovasc Intervent Radiol 2015; 38: 143-151. [PMID: 24806953. DOI: 10.1007/s00270-014-0897-y
52. Bale R, Widmann G, Schullian P, Haidu M, Pall G, Klaus A, Weiss H, Biebl M, Margreiter R. Percutaneous stereotactic radiofrequency ablation of colorectal liver metastases. Eur Radiol 2012; 22: 930-937. [PMID: 22071776. DOI: 10.1007/s00330-011-2314-0
53. Gillams AR, Lees WR. Radio-frequency ablation of colorectal liver metastases in 167 patients. Eur Radiol 2004; 14: 2261-2267. [PMID: 15599547. DOI: 10.1007/s00330-004-2416-z
54. Devun F, Biau J, Huerre M, Croset A, Sun JS, Denys A, Dutreix M. Colorectal cancer metastasis: the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation. Radiology 2014; 270: 736-746. [PMID: 24475822. DOI: 10.1148/radiol.13130805
55. Sag AA, Maybody M, Comstock C, Solomon SB. Percutaneous image-guided ablation of breast tumors: an overview. Semin Intervent Radiol 2014; 31: 193-202. [PMID: 25049447. DOI: 10.1055/s-0034-1376159
56. Erinjeri JP, Clark TW. Cryoablation: mechanism of action and devices. J Vasc Interv Radiol 2010; 21: S187-S191. [PMID: 20656228. DOI: 10.1016/j.jvir.2009.12.403
57. Maybody M. An overview of image-guided percutaneous ablation of renal tumors. Semin Intervent Radiol 2010; 27: 261-267. [PMID: 22550365. DOI: 10.1055/s-0030-1261784
58. Groeschl RT, Pilgrim CH, Hanna EM, Simo KA, Swan RZ, Sindram D, Martinie JB, Iannitti DA, Bloomston M, Schmidt C, Khabiri H, Shirley LA, Martin RC, Tsai S, Turaga KK, Christians KK, Rilling WS, Gamblin TC. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg 2014; 259: 1195-1200. [PMID: 24096760. DOI: 10.1097/sla.0000000000000234
59. Shibata T, Niinobu T, Ogata N, Takami M. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer 2000; 89: 276-284. [PMID: 10918156
60. Cannon R, Ellis S, Hayes D, Narayanan G, Martin RC. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol 2013; 107: 544-549. [PMID: 23090720. DOI: 10.1002/jso.23280
61. Kingham TP, Karkar AM, D'Angelica MI, Allen PJ, Dematteo RP, Getrajdman GI, Sofocleous CT, Solomon SB, Jarnagin WR, Fong Y. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg 2012; 215: 379-387. [PMID: 22704820. DOI: 10.1016/j.jamcollsurg.2012.04.029
62. Silk MT, Wimmer T, Lee KS, Srimathveeravalli G, Brown KT, Kingham PT, Fong Y, Durack JC, Sofocleous CT, Solomon SB. Percutaneous ablation of peribiliary tumors with irreversible electroporation. J Vasc Interv Radiol 2014; 25: 112-118. [PMID: 24262034. DOI: 10.1016/j.jvir.2013.10.012
63. Thomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, Loader-Oliver D, Roberts S, Evans P, Ball C, Haydon A. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 2011; 22: 611-621. [PMID: 21439847. DOI: 10.1016/j.jvir.2010.12.014
64. Erinjeri JP, Thomas CT, Samoilia A, Fleisher M, Gonen M, Sofocleous CT, Thornton RH, Siegelbaum RH, Covey AM, Brody LA, Alago W, Maybody M, Brown KT, Getrajdman GI, Solomon SB. Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10. J Vasc Interv Radiol 2013; 24: 1105-1112. [PMID: 23582441. DOI: 10.1016/j.jvir.2013.02.015
65. Ryan ER, Sofocleous CT, Schöder H, Carrasquillo JA, Nehmeh S, Larson SM, Thornton R, Siegelbaum RH, Erinjeri JP, Solomon SB. Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. Radiology 2013; 268: 288-295. [PMID: 23564714. DOI: 10.1148/radiol.13121462
66. Maybody M, Stevenson C, Solomon SB. Overview of navigation systems in image-guided interventions. Tech Vasc Interv Radiol 2013; 16: 136-143. [PMID: 23993075. DOI: 10.1053/j.tvir.2013.02.008
67. Elnekave E, Erinjeri JP, Brown KT, Thornton RH, Petre EN, Maybody M, Maluccio MA, Hsu M, Sofocleous CT, Getrajdman GI, Brody LA, Solomon SB, Alago W, Fong Y, Jarnagin WR, Covey AM. Long-Term outcomes comparing surgery to embolization-Ablation for treatment of solitary HCC& lt; 7 cm. Ann Surg Oncol 2013; 20: 2881-2886. [PMID: 23563960. DOI: 10.1245/s10434-013-2961-2
68. Long-Term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK). Lancet 1995; 345: 349-353. [PMID: 7845115
69. Laffer U, Metzger U, Aeberhard P, Lorenz M, Harder F, Maibach R, Zuber M, Herrmann R. Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer: long-Term results of a randomized controlled trial. Int J Colorectal Dis 2008; 23: 1233-1241. [PMID: 18688620. DOI: 10.1007/s00384-008-0543-8
70. Erinjeri JP, Salhab HM, Covey AM, Getrajdman GI, Brown KT. Arterial patency after repeated hepatic artery bland particle embolization. J Vasc Interv Radiol 2010; 21: 522-526. [PMID: 20188589. DOI: 10.1016/j.jvir.2009.12.390
71. Tanaka T, Nishiofuku H, Maeda S, Masada T, Anai H, Sakaguchi H, Kichikawa K. Repeated bland-TAE using small microspheres injected via an implantable port-catheter system for liver metastases: an initial experience. Cardiovasc Intervent Radiol 2014; 37: 493-497. [PMID: 23839008. DOI: 10.1007/s00270-013-0691-2
72. Tanaka T, Isfort P, Braunschweig T, Westphal S, Woitok A, Penzkofer T, Bruners P, Kichikawa K, Schmitz-Rode T, Mahnken AH. Superselective particle embolization enhances efficacy of radiofrequency ablation: effects of particle size and sequence of action. Cardiovasc Intervent Radiol 2013; 36: 773-782. [PMID: 23070107. DOI: 10.1007/s00270-012-0497-7
73. Kruskal JB, Hlatky L, Hahnfeldt P, Teramoto K, Stokes KR, Clouse ME. In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol 1993; 4: 741-747. [PMID: 8280994
74. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171. [PMID: 11981766. DOI: 10.1053/jhep.2002.33156
75. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739. [PMID: 12049862. DOI: 10.1016/s0140-6736(02)08649-x
76. Taylor RR, Tang Y, Gonzalez MV, Stratford PW, Lewis AL. Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci 2007; 30: 7-14. [PMID: 17030118. DOI: 10.1016/j.ejps.2006.09.002
77. Albert M, Kiefer MV, Sun W, Haller D, Fraker DL, Tuite CM, Stavropoulos SW, Mondschein JI, Soulen MC. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 2011; 117: 343-352. [PMID: 20830766. DOI: 10.1002/cncr.25387
78. Aliberti C, Tilli M, Benea G, Fiorentini G. Trans-Arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res 2006; 26: 3793-3795. [PMID: 17094403
79. Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, Mambrini A, Montagnani F, Alessandroni P, Catalano V, Coschiera P. Intra-Arterial infusion of irinotecan-loaded drugeluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012; 32: 1387-1395. [PMID: 22493375
80. Martin RC, Howard J, Tomalty D, Robbins K, Padr R, Bosnjakovic PM, Tatum C. Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multiinstitutional registry. Cardiovasc Intervent Radiol 2010; 33: 960-966. [PMID: 20661569. DOI: 10.1007/s00270-010-9937-4
81. Tellez C, Benson AB, Lyster MT, Talamonti M, Shaw J, Braun MA, Nemcek AA, Vogelzang RL. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 1998; 82: 1250-1259. [PMID: 9529016
82. Vogl TJ, Gruber T, Balzer JO, Eichler K, Hammerstingl R, Zangos S. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology 2009; 250: 281-289. [PMID: 19092099. DOI: 10.1148/radiol.2501080295
83. Iezzi R, Marsico VA, Guerra A, Cerchiaro E, Cassano A, Basso M, Devicienti E, Rodolfino E, Barone C, Bonomo L. Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study. Cardiovasc Intervent Radiol 2015; 38: 1523-1531. [PMID: 25799948. DOI: 10.1007/s00270-015-1080-9
84. Reddy SK, Kesmodel SB, Alexander HR. Isolated hepatic perfusion for patients with liver metastases. Ther Adv Med Oncol 2014; 6: 180-194. [PMID: 25057304. DOI: 10.1177/1758834014529175
85. Kennedy A. Radioembolization of hepatic tumors. J Gastrointest Oncol 2014; 5: 178-189. [PMID: 24982766. DOI: 10.3978/j.issn.2078-6891.2014.037
86. Kennedy AS, Coldwell D, Nutting C, Murthy R, Wertman DE, Loehr SP, Overton C, Meranze S, Niedzwiecki J, Sailer S. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006; 65: 412-425. [PMID: 16690429. DOI: 10.1016/j.ijrobp.2005.12.051
87. Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, Gebski V. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001; 12: 1711-1720. [PMID: 11843249
88. Sa g AA, S a v i n M A , L a l N R , M e h t a R R . Y t t r i u m-9 0 radioembolization of malignant tumors of the liver: gallbladder effects. AJR Am J Roentgenol 2014; 202: 1130-1135. [PMID: 24758670. DOI: 10.2214/AJR.13.10548
89. Atassi B, Bangash AK, Lewandowski RJ, Ibrahim S, Kulik L, Mulcahy MF, Murthy R, Ryu RK, Sato KT, Miller FH, Omary RA, Salem R. Biliary sequelae following radioembolization with Yttrium-90 microspheres. J Vasc Interv Radiol 2008; 19: 691-697. [PMID: 18440457. DOI: 10.1016/j.jvir.2008.01.003
90. Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, Cardaci G, Gray B. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004; 88: 78-85. [PMID: 15499601. DOI: 10.1002/jso.20141
91. Fong Y, Kim T, Bhargava A, Schwartz L, Brown K, Brody L, Covey A, Karrasch M, Getrajdman G, Mescheder A, Jarnagin W, Kemeny N. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther 2009; 17: 389-394. [PMID: 19018254. DOI: 10.1038/mt.2008.240
92. Mori M, Tomoda H, Ishida T, Kido A, Shimono R, Matsushima T, Kuwano H, Sugimachi K. Surgical resection of pulmonary metastases from colorectal adenocarcinoma. Special reference to repeated pulmonary resections. Arch Surg 1991; 126: 1297-1301; discussion 1302. [PMID: 1929833
93. Pastorino U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, Johnston M, McCormack P, Pass H, Putnam JB. Long-Term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 1997; 113: 37-49. [PMID: 9011700
94. Saito Y, Omiya H, Kohno K, Kobayashi T, Itoi K, Teramachi M, Sasaki M, Suzuki H, Takao H, Nakade M. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment. J Thorac Cardiovasc Surg 2002; 124: 1007-1013. [PMID: 12407386. DOI: 10.1067/mtc.2002.125165
95. Watanabe K, Nagai K, Kobayashi A, Sugito M, Saito N. Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer. Br J Surg 2009; 96: 1058-1065. [PMID: 19672932. DOI: 10.1002/bjs.6682
96. Lencioni R, Crocetti L, Cioni R, Suh R, Glenn D, Regge D, Helmberger T, Gillams AR, Frilling A, Ambrogi M, Bartolozzi C, Mussi A. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-To-Treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol 2008; 9: 621-628. [PMID: 18565793. DOI: 10.1016/S1470-2045(08)70155-4
97. Yan TD, King J, Sjarif A, Glenn D, Steinke K, Al-Kindy A, Morris DL. Treatment failure after percutaneous radiofrequency ablation for nonsurgical candidates with pulmonary metastases from colorectal carcinoma. Ann Surg Oncol 2007; 14: 1718-1726. [PMID: 17285398. DOI: 10.1245/s10434-006-9271-x
98. Gillams A, Khan Z, Osborn P, Lees W. Survival after radiofrequency ablation in 122 patients with inoperable colorectal lung metastases. Cardiovasc Intervent Radiol 2013; 36: 724-730. [PMID: 23070108. DOI: 10.1007/s00270-012-0500-3
99. Hiraki T, Gobara H, Iishi T, Sano Y, Iguchi T, Fujiwara H, Tajiri N, Sakurai J, Date H, Mimura H, Kanazawa S. Percutaneous radiofrequency ablation for pulmonary metastases from colorectal cancer: midterm results in 27 patients. J Vasc Interv Radiol 2007; 18: 1264-1269. [PMID: 17911517. DOI: 10.1016/j.jvir.2007.06.027
100. Petre EN, Jia X, Thornton RH, Sofocleous CT, Alago W, Kemeny NE, Solomon SB. Treatment of pulmonary colorectal metastases by radiofrequency ablation. Clin Colorectal Cancer 2013; 12: 37-44. [PMID: 23026111. DOI: 10.1016/j.clcc.2012.07.003
101. Yamakado K, Hase S, Matsuoka T, Tanigawa N, Nakatsuka A, Takaki H, Takao M, Inoue Y, Kanazawa S, Inoue Y, Sawada S, Kusunoki M, Takeda K. Radiofrequency ablation for the treatment of unresectable lung metastases in patients with colorectal cancer: a multicenter study in Japan. J Vasc Interv Radiol 2007; 18: 393-398. [PMID: 17377185. DOI: 10.1016/j.jvir.2006.11.003
102. Yamauchi Y, Izumi Y, Kawamura M, Nakatsuka S, Yashiro H, Tsukada N, Inoue M, Asakura K, Nomori H. Percutaneous cryoablation of pulmonary metastases from colorectal cancer. PLoS One 2011; 6: e27086. [PMID: 22096520 10.1371/journal. pone 0027086
103. Vogl TJ, Naguib NN, Gruber-Rouh T, Koitka K, Lehnert T, Nour-Eldin NE. Microwave ablation therapy: clinical utility in treatment of pulmonary metastases. Radiology 2011; 261: 643-651. [PMID: 22012906. DOI: 10.1148/radiol.11101643
104. Shah A, Udwadia ZF, Almel S. Oxaliplatin-induced lung fibrosis. Indian J Med Paediatr Oncol 2009; 30: 116-118. [PMID: 20838550. DOI: 10.4103/0971-5851.64259
105. Chan AK, Choo BA, Glaholm J. Pulmonary toxicity with oxaliplatin and capecitabine/5-Fluorouracil chemotherapy: a case report and review of the literature. Onkologie 2011; 34: 443-446. [PMID: 21934344. DOI: 10.1159/000331133
106. Shimura T, Fuse N, Yoshino T, Minashi K, Tahara M, Doi T, Joh T, Ohtsu A. Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. Ann Oncol 2010; 21: 2005-2010. [PMID: 20305036. DOI: 10.1093/annonc/mdq061
107. Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 2006; 17: 372-379. [PMID: 16291774. DOI: 10.1093/annonc/mdj057
108. Hildebrand P, Kleemann M, Roblick UJ, Mirow L, Birth M, Leibecke T, Bruch HP. Radiofrequency-Ablation of unresectable primary and secondary liver tumors: results in 88 patients. Langenbecks Arch Surg 2006; 391: 118-123. [PMID: 16604376. DOI: 10.1007/s00423-006-0024-x
109. Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 2007; 246: 559-565; discussion 565-567. [PMID: 17893492. DOI: 10.1097/SLA.0b013e318155a7b6
110. Berber E, Tsinberg M, Tellioglu G, Simpfendorfer CH, Siperstein AE. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg 2008; 12: 1967-1972. [PMID: 18688683. DOI: 10.1007/s11605-008-0622-8
111. Veltri A, Sacchetto P, Tosetti I, Pagano E, Fava C, Gandini G. Radiofrequency ablation of colorectal liver metastases: small size favorably predicts technique effectiveness and survival. Cardiovasc Intervent Radiol 2008; 31: 948-956. [PMID: 18506519. DOI: 10.1007/s00270-008-9362-0
112. Gleisner AL, Choti MA, Assumpcao L, Nathan H, Schulick RD, Pawlik TM. Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg 2008; 143: 1204-1212. [PMID: 19075173. DOI: 10.1001/archsurg.143.12.1204
113. Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 2009; 19: 1206-1213. [PMID: 19137310. DOI: 10.1007/s00330-008-1258-5
114. Sofocleous CT, Petre EN, Gonen M, Brown KT, Solomon SB, Covey AM, Alago W, Brody LA, Thornton RH, D'Angelica M, Fong Y, Kemeny NE. CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy. J Vasc Interv Radiol 2011; 22: 755-761. [PMID: 21514841. DOI: 10.1016/j.jvir.2011.01.451
115. Solbiati L, Ahmed M, Cova L, Ierace T, Brioschi M, Goldberg SN. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-Term survival with up to 10-year follow-up. Radiology 2012; 265: 958-968. [PMID: 23091175. DOI: 10.1148/radiol.12111851
116. Hamada A, Yamakado K, Nakatsuka A, Uraki J, Kashima M, Takaki H, Yamanaka T, Inoue Y, Kusunoki M, Takeda K. Radiofrequency ablation for colorectal liver metastases: prognostic factors in non-surgical candidates. Jpn J Radiol 2012; 30: 567-574. [PMID: 22664831. DOI: 10.1007/s11604-012-0089-0
117. Rivoire M, De Cian F, Meeus P, Négrier S, Sebban H, Kaemmerlen P. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 2002; 95: 2283-2292. [PMID: 12436433. DOI: 10.1002/cncr.10973
118. Yan DB, Clingan P, Morris DL. Hepatic cryotherapy and regional chemotherapy with or without resection for liver metastases from colorectal carcinoma: how many are too many? Cancer 2003; 98: 320-330. [PMID: 12872352. DOI: 10.1002/cncr.11498
119. Brooks AJ, Wang F, Alfredson M, Yan TD, Morris DL. Synchronous liver resection and cryotherapy for colorectal metastases: survival analysis. Surgeon 2005; 3: 265-268. [PMID: 16121772
120. Niu R, Yan TD, Zhu JC, Black D, Chu F, Morris DL. Recurrence and survival outcomes after hepatic resection with or without cryotherapy for liver metastases from colorectal carcinoma. Ann Surg Oncol 2007; 14: 2078-2087. [PMID: 17473951. DOI: 10.1245/s10434-007-9400-1
121. Paganini AM, Rotundo A, Barchetti L, Lezoche E. Cryosurgical ablation of hepatic colorectal metastases. Surg Oncol 2007; 16 Suppl 1: S137-S140. [PMID: 18055196. DOI: 10.1016/j.suronc.2007.10.031
122. Ng KM, Chua TC, Saxena A, Zhao J, Chu F, Morris DL. Two decades of experience with hepatic cryotherapy for advanced colorectal metastases. Ann Surg Oncol 2012; 19: 1276-1283. [PMID: 21913018. DOI: 10.1245/s10434-011-2025-4
123. Shyn PB, Mauri G, Alencar RO, Tatli S, Shah SH, Morrison PR, Catalano PJ, Silverman SG. Percutaneous imaging-guided cryoablation of liver tumors: predicting local progression on 24-hour MRI. AJR Am J Roentgenol 2014; 203: W181-W191. [PMID: 24555531. DOI: 10.2214/ajr.13.10747
124. Liang P, Dong B, Yu X, Yang Y, Yu D, Su L, Xiao Q, Sheng L. Prognostic factors for percutaneous microwave coagulation therapy of hepatic metastases. AJR Am J Roentgenol 2003; 181: 1319-1325. [PMID: 14573427. DOI: 10.2214/ajr.181.5.1811319
125. Tanaka K, Shimada H, Nagano Y, Endo I, Sekido H, Togo S. Outcome after hepatic resection versus combined resection and microwave ablation for multiple bilobar colorectal metastases to the liver. Surgery 2006; 139: 263-273. [PMID: 16455336. DOI: 10.1016/j.surg.2005.07.036
126. Lang EK, Brown CL. Colorectal metastases to the liver: selective chemoembolization. Radiology 1993; 189: 417-422. [PMID: 8210369. DOI: 10.1148/radiology.189.2.8210369
127. Hong K, McBride JD, Georgiades CS, Reyes DK, Herman JM, Kamel IR, Geschwind JF. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol 2009; 20: 360-367. [PMID: 19167245. DOI: 10.1016/j.jvir.2008.11.019
128. Martin RC, Joshi J, Robbins K, Tomalty D, Bosnjakovik P, Derner M, Padr R, Rocek M, Scupchenko A, Tatum C. Hepatic intra-Arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 2011; 18: 192-198. [PMID: 20740319. DOI: 10.1245/s10434-010-1288-5
129. Narayanan G, Barbery K, Suthar R, Guerrero G, Arora G. Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer. Anticancer Res 2013; 33: 2077-2083. [PMID: 23645758
130. Sharma RA, Van Hazel GA, Morgan B, Berry DP, Blanshard K, Price D, Bower G, Shannon JA, Gibbs P, Steward WP. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007; 25: 1099-1106. [PMID: 17369573. DOI: 10.1200/JCO.2006.08.7916
131. Benson AB, Geschwind JF, Mulcahy MF, Rilling W, Siskin G, Wiseman G, Cunningham J, Houghton B, Ross M, Memon K, Andrews J, Fleming CJ, Herman J, Nimeiri H, Lewandowski RJ, Salem R. Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer 2013; 49: 3122-3130. [PMID: 23777743. DOI: 10.1016/j.ejca.2013.05.012
132. Lewandowski RJ, Memon K, Mulcahy MF, Hickey R, Marshall K, Williams M, Salzig K, Gates VL, Atassi B, Vouche M, Atassi R, Desai K, Hohlastos E, Sato K, Habib A, Kircher S, Newman SB, Nimeiri H, Benson AB, Salem R. Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy. Eur J Nucl Med Mol Imaging 2014; 41: 1861-1869. [PMID: 24906565. DOI: 10.1007/s00259-014-2799-2
133. Sofocleous CT, Garcia AR, Pandit-Taskar N, Do KG, Brody LA, Petre EN, Capanu M, Longing AP, Chou JF, Carrasquillo JA, Kemeny NE. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. Clin Colorectal Cancer 2014; 13: 27-36. [PMID: 24370352. DOI: 10.1016/j.clcc.2013.11.010
134. Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, De Keukeleire K, Verslype C, Defreyne L, Van Cutsem E, Delatte P, Delaunoit T, Personeni N, Paesmans M, Van Laethem JL, Flamen P. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28: 3687-3694. [PMID: 20567019. DOI: 10.1200/jco.2010.28.5643
135. Gibbs P, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as firstline treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. BMC Cancer 2014; 14: 897. [PMID: 25487708. DOI: 10.1186/1471-2407-14-897
136. Dutton SJ, Kenealy N, Love SB, Wasan HS, Sharma RA. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer 2014; 14: 497. [PMID: 25011439. DOI: 10.1186/1471-2407-14-497
137. EPOCH Clinical Trial Information. Available from: URL: http://www.theraspheretrials.com/epoch-102